BNIP3 and ovarian cancer: A comparative analysis and a patient‐matched analysis of 112 primary ovarian carcinoma and 63 metastatic samples reported by Nymoen et al. [32] showed that BNIP3 levels were significantly lower in metastatic sites than in primary ovarian cancer lesions.